<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="87">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 16, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02259582</url>
  </required_header>
  <id_info>
    <org_study_id>M18-007</org_study_id>
    <nct_id>NCT02259582</nct_id>
  </id_info>
  <brief_title>A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer</brief_title>
  <acronym>DENALI</acronym>
  <official_title>A 2-Arm Phase 2 Double-Blind Randomized Study of Carboplatin, Pemetrexed Plus Placebo Versus Carboplatin, Pemetrexed Plus Truncated Demcizumab as First-Line Treatment in Subjects With Stage IV Non-Squamous Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OncoMed Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>OncoMed Pharmaceuticals, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind, 3-arm (1:1:1) study in subjects with first-line Stage IV
      non-squamous NSCLC. The purpose is to test the efficacy and safety of demcizumab, when given
      in combination with carboplatin and pemetrexed compared to placebo. The administration of
      carboplatin and pemetrexed is a standard treatment for patients with non-squamous non-small
      cell lung cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be enrolled at centers in North America, Western Europe, Australia and New
      Zealand. Up to 28 days (4 weeks) prior to treatment.

      If enrolled in the study, you will receive intravenous (in the vein) infusions of demcizumab
      (or placebo), carboplatin, and pemetrexed administered on the same day, every 21 days for 4
      cycles, or until it has been shown that your cancer has gotten worse. If your physician
      decides to delay treatment with one of the agents due to side effects, the other agents may
      still be administered as scheduled. After 4 cycles, if you have stable or improved disease,
      you will continue to receive pemetrexed once every 21 days as maintenance therapy. After 8
      cycles, if you have stable or improved disease, you may receive demcizumab (or placebo),
      every 21 days for 4 more cycles.

      You will undergo assessments every 6 weeks to determine the status of your disease.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Investigator-assessed median progression-free survival (PFS)</measure>
    <time_frame>Assessed at baseline and every 6 weeks, from randomization until death or disease progression, up to 26.1 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Investigator-assessed median progression-free survival as assessed by RECIST v1.1 in Arm 1 to Arm 2 and Arm 1 to Arm 3</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigator-assessed RECIST v1.1 response rate</measure>
    <time_frame>Assessed at baseline and every 6 weeks up to 26.1 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Investigator-assessed RECIST v1.1 response rate in Arm 1 to Arm 2 and Arm 1 to Arm 3</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">201</enrollment>
  <condition>Nonsquamous Nonsmall Cell Neoplasm of Lung</condition>
  <arm_group>
    <arm_group_label>Arm 1 Pem, carbo, placebo x 4 cycles</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Pemetrexed (500 mg/m2),carboplatin (area under the concentration-time curve of 6 mg/mL x min) once every 21 days X 4 cycles, pemetrexed maintenance and placebo starting at Day 84</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 Pem, carbo x 4 cycles, one course of dem</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pemetrexed (500 mg/m2), carboplatin (area under the concentration-time curve of 6 mg/mL x min) x 4 cycles, one course of demcizumab 5mg/kg, maintenance pemetrexed + placebo starting on Day 84</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3 pem, carbo, dem x 4 cycles, dem retreatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pemetrexed (500 mg/m2), carboplatin (area under the concentration-time curve of 6 mg/mL x min) x 4 cycles, maintenance pemetrexed starting on Day 84. 2 courses of demcizumab 5 mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <arm_group_label>Arm 1 Pem, carbo, placebo x 4 cycles</arm_group_label>
    <arm_group_label>Arm 2 Pem, carbo x 4 cycles, one course of dem</arm_group_label>
    <arm_group_label>Arm 3 pem, carbo, dem x 4 cycles, dem retreatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <arm_group_label>Arm 1 Pem, carbo, placebo x 4 cycles</arm_group_label>
    <arm_group_label>Arm 2 Pem, carbo x 4 cycles, one course of dem</arm_group_label>
    <arm_group_label>Arm 3 pem, carbo, dem x 4 cycles, dem retreatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>demcizumab</intervention_name>
    <arm_group_label>Arm 2 Pem, carbo x 4 cycles, one course of dem</arm_group_label>
    <arm_group_label>Arm 3 pem, carbo, dem x 4 cycles, dem retreatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          1. Signed Informed Consent Form

          2. Histologically or cytologically confirmed Stage IV non-squamous NSCLC

          3. Availability of FFPE tumor tissue, either fresh core-needle-biopsied or archived

          4. Age &gt; or = to 21 years

          5. ECOG performance status of 0 or 1

          6. Disease that is measurable per RECIST v1.1

          7. Adequate organ and marrow function

          8. For women of childbearing potential, agreement to use two effective forms of
             contraception

        Main Exclusion Criteria:

          1. Histologically or cytologically documented, advanced, mixed non-small cell and small
             cell tumors or mixed adenosquamous carcinomas

          2. NSCLC with known EGFR mutation or anaplastic lymphoma kinase (ALK) gene translocation
             (such as EML4-ALK)

          3. Prior or ongoing therapy (including chemotherapy, antibody therapy, tyrosine kinase
             inhibitors, radiotherapy, immunotherapy, hormonal therapy, or investigational
             therapy) for the treatment of Stage IV non-squamous NSCLC

          4. Evidence of tumor invading major blood vessels, cavitation of one or more pulmonary
             tumor mass(es) ortracheo-esophageal fistula

          5. Brain metastases, leptomeningeal disease, uncontrolled seizure disorder, or active
             neurologic disease

          6. Malignancies other than non-squamous NSCLC successfully treated within 3 years prior
             to randomization (with the exception of certain early-stage cancers)

          7. History of a significant allergic reaction attributed to humanized or human
             monoclonal antibody therapy

          8. Significant intercurrent illness defined as an illness that may result in the
             subject's death prior to their death from non-squamous NSCLC and/or significantly
             limit their ability to comply with the requirements of this study

          9. Recent hemoptysis &gt;2.5 mL or serious bleeding from another site, known bleeding
             disorder or coagulopathy or therapeutic anti-coagulation

         10. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             prior to randomization, or anticipation of need for major surgical procedure during
             the course of the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rainer Brachmann, MD</last_name>
    <phone>650-995-8221</phone>
    <email>Rainer.Brachmann@oncomed.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Desert Hematology Oncology Medical Group, Inc.</name>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <zip>92270</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luke Dreisbach, MD</last_name>
      <phone>760-568-3613</phone>
      <email>researchdho@aol.com</email>
    </contact>
    <investigator>
      <last_name>Luke Dreisbach, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>. 94143-1705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eddie Sosa</last_name>
      <phone>415-514-6241</phone>
      <email>Eduardo.Sosa@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Matthew Gubens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Smilow Cancer Hospital at Yale-New Haven</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510-3221</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Chiang, MD</last_name>
      <phone>203-785-6879</phone>
      <email>anne.chiang@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Anne Chiang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ocala Oncology Center</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Liebmann, BS, LPN, CRC</last_name>
      <phone>352-732-4938</phone>
      <email>amy.liebmann@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Craig H. Reynolds, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Edward H. Kaplan MD &amp; Associates</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>60076</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edward H Kaplan, MD</last_name>
      <phone>847-675-3900</phone>
    </contact>
    <investigator>
      <last_name>Edward H Kaplan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Anne Arundel Medical Center</name>
      <address>
        <city>Annapolis</city>
        <state>Maryland</state>
        <zip>21401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Graze, MD</last_name>
      <phone>443-481-4884</phone>
      <email>pgraze@aahs.org</email>
    </contact>
    <investigator>
      <last_name>Peter Graze, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haythem Ali, MD</last_name>
    </contact>
    <investigator>
      <last_name>Haythem Ali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>4820I</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Broome Oncology, LLC</name>
      <address>
        <city>Binghamton</city>
        <state>New York</state>
        <zip>13905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ronald P. Harris, DO</last_name>
      <phone>607-763-8065</phone>
    </contact>
    <investigator>
      <last_name>Ronald P. Harris, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grace Dy, MD</last_name>
    </contact>
    <investigator>
      <last_name>Grace Dy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Associates of Rockland</name>
      <address>
        <city>Nyack</city>
        <state>New York</state>
        <zip>10960</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bradley Cohen, MD</last_name>
      <phone>845-362-1750</phone>
    </contact>
    <investigator>
      <last_name>Bradley Cohen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gaston Hematology &amp; Oncology</name>
      <address>
        <city>Gastonia</city>
        <state>North Carolina</state>
        <zip>28054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Charles, MD</last_name>
      <phone>704-865-5210</phone>
    </contact>
    <investigator>
      <last_name>William Charles, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center Research</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nashat Gabrail, MD</last_name>
      <phone>330-492-3345</phone>
    </contact>
    <investigator>
      <last_name>Nashat Gabrail, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Cleveland</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Afshin Dowlati, MD</last_name>
      <phone>216-844-1228</phone>
      <email>afshin.dowlati@uhhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Afshin Dowlati, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Baylor Charles A. Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kartik Konduri,, MD</last_name>
    </contact>
    <investigator>
      <last_name>Kartik Konduri,, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch at Galveston</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maurice Willis, MD</last_name>
    </contact>
    <investigator>
      <last_name>Maurice Willis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Sherman</name>
      <address>
        <city>North Shennan</city>
        <state>Texas</state>
        <zip>75090-0504</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tammy E. Roque, MD</last_name>
    </contact>
    <investigator>
      <last_name>Tammy E. Roque, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Compass Oncology</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98684</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Papenfuse, RN CRC</last_name>
      <phone>360-449-6521</phone>
      <email>susan.papenfuse@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>DAVID A SMITH, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chris O'Brien Lifehouse</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Joseph Boyer, MD</last_name>
    </contact>
    <investigator>
      <last_name>Michael Joseph Boyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Kinghorn Cancer Centre</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Grygiel, MD</last_name>
    </contact>
    <investigator>
      <last_name>John Grygiel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Coast Cancer Institute Port Macquarie Base Hospital</name>
      <address>
        <city>Port Macquarie</city>
        <state>New South Wales</state>
        <zip>2444</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Baerin B Houghton, MD</last_name>
      <phone>6582-3534</phone>
      <email>bh@oncoresp.com.aui</email>
    </contact>
    <investigator>
      <last_name>Baerin B Houghton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Coast Cancer Institute Port Macquarie Base Hospital</name>
      <address>
        <city>Port Macquarie</city>
        <state>New South Wales</state>
        <zip>2444</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Baerin Houghton, MD</last_name>
      <phone>+65823534</phone>
      <email>bh@oncoresp.com.au</email>
    </contact>
    <investigator>
      <last_name>Baerin Houghton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royall Brisbane &amp; Women's Hospital</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gordon Hughes, MD</last_name>
      <phone>+61 7 3636 8111</phone>
      <email>brett.hughes@health.qld.gov.au</email>
    </contact>
    <investigator>
      <last_name>Gordon Hughes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icon Cancer Foundation</name>
      <address>
        <city>Milton</city>
        <state>Queensland</state>
        <zip>4064</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul N Mainwaring, MD</last_name>
      <phone>+0737374500</phone>
      <email>pmainwaring@iconcancercare.com.au</email>
    </contact>
    <investigator>
      <last_name>Paul N Mainwaring, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Queen Elizabeth Hospital</name>
      <address>
        <city>Woodville South</city>
        <state>South Australia</state>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Roberts-Thomson, MD</last_name>
    </contact>
    <investigator>
      <last_name>Rachel Roberts-Thomson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Monash Health, Monash Cancer Centre-Moorabbin</name>
      <address>
        <city>East Bentleigh</city>
        <state>Victoria</state>
        <zip>3165</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin Markman, MD</last_name>
      <phone>+61399288120</phone>
    </contact>
    <investigator>
      <last_name>Benjamin Markman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. John of God Subiaco Hospital</name>
      <address>
        <city>Subiaco</city>
        <state>Western Australia</state>
        <zip>6008</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ziekenhuisnetwerk Antwerpen- Koningin Paola Kinderzickenhuis</name>
      <address>
        <city>Antwerpen</city>
        <zip>2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniella Galdermans, MD</last_name>
    </contact>
    <investigator>
      <last_name>Daniella Galdermans, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Grand Hopital de Charleroi- Site Notre-Dame</name>
      <address>
        <city>Charleroi</city>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe Lonchay, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christophe Lonchay, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Jolimont-Lobbes</name>
      <address>
        <city>La Louviere</city>
        <zip>7100</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHR de Ia Citadelle</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frederique Bustin, MD</last_name>
    </contact>
    <investigator>
      <last_name>Frederique Bustin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Istituti Ospitalieri</name>
      <address>
        <city>Cremona</city>
        <state>Lombardia</state>
        <zip>26100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rodolfo Passalacqua, MD</last_name>
      <phone>+390372405242</phone>
      <email>r.passalacqua@ospedale.cremona.it</email>
    </contact>
    <investigator>
      <last_name>Rodolfo Passalacqua, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Città della Salute e della Scienza di Torino</name>
      <address>
        <city>Torino</city>
        <state>Piemonte</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Libero Ciuffreda, MD</last_name>
      <phone>+390116335580</phone>
      <email>lciuffreda@cittadellasalute.to.it</email>
    </contact>
    <investigator>
      <last_name>Libero Ciuffreda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Smilow Cancer Hospital at Yale-New Haven</name>
      <address>
        <city>Aviano</city>
        <state>Pordenone</state>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandra Bearz, MD</last_name>
      <phone>+390434659294</phone>
      <email>abearz@cro.it</email>
    </contact>
    <investigator>
      <last_name>Alessandra Bearz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Pisana</name>
      <address>
        <city>Pisa</city>
        <state>Toscana</state>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sergio Ricci, MD</last_name>
      <phone>+39050992145</phone>
      <email>s.ricci@ao-pisa.toscana.it</email>
    </contact>
    <investigator>
      <last_name>Sergio Ricci, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesus Montesinos Mufloz, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jesus Montesinos Mufloz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute Catalan de Oncologia (ICO L'Hospitalet)</name>
      <address>
        <city>L 'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ernest Alforja Nadal, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ernest Alforja Nadal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta de Hierro Majadahonda</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariano Pulla Provencio, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mariano Pulla Provencio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Nuestra Senora de Sonsoles</name>
      <address>
        <city>Avila</city>
        <zip>05004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Enrique Ales Martinez, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Jose Enrique Ales Martinez, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall D'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol</name>
      <address>
        <city>Barcelona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañon</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramon García Gómez, MD</last_name>
      <phone>+34914265218</phone>
      <email>ramon.garcia@salud.madrid.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Luis Gonzalez Larriba, MD</last_name>
      <phone>+34913303546</phone>
      <email>jglarriba@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>Jose Luis Gonzalez Larriba, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Madrid Universitario Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esther Martin H Holgado, MD</last_name>
    </contact>
    <investigator>
      <last_name>Esther Martin H Holgado, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesus Corral Jaime, MD</last_name>
      <phone>+34955013062</phone>
      <email>jesuscorraljaime@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Jesus Corral Jaime, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <lastchanged_date>February 25, 2016</lastchanged_date>
  <firstreceived_date>September 17, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 2</keyword>
  <keyword>histologically</keyword>
  <keyword>confirmed</keyword>
  <keyword>malignancy</keyword>
  <keyword>metastatic</keyword>
  <keyword>pemetrexed</keyword>
  <keyword>carboplatin</keyword>
  <keyword>carcinoma</keyword>
  <keyword>non small cell lung</keyword>
  <keyword>lung neoplasms</keyword>
  <keyword>lung diseases</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
